iPS Cells & Regenerative Medicine Weekly Report July 5, 2026

iPS Cells & Regenerative Medicine Weekly Report July 12, 2026

Vector BioMed Proposes Platform to Accelerate CAR-T Therapy Development from Gene Sequence to Clinic-Ready in Under 12 Months

Cellistic Unveils Specialized CDMO Services for iPSC-Derived Cell Therapies, Expediting Development from Early Stages to GMP

Taiwan’s ITRI Establishes Highly Stable iPSC-Based MSC and Exosome Manufacturing Platform to Advance Regenerative Medicine

Imunopharm Files for Shanghai STAR Market IPO, Targeting $550 Million Valuation to Expand CAR-T and CDMO Business

ICR Unveils New ‘DOSET’ Statistical Approach to Optimize Early-Stage Cancer Clinical Trials for CAR-T and Advanced Therapies

Hospital Capacity, Not Just Manufacturing, Identified as True Bottleneck for CAR-T Therapy Commercialization

Porton Advanced’s UC-MSC Cell Bank for Exosome Manufacturing Receives FDA Drug Master File (DMF) Acceptance